Starbucks' 'fall from grace' that precipitated CEO Narasimhan's untimely exit
Howard Schultz - Narasimhan's predecessor and a celebrated CEO and founder - had in May said that Starbucks needed to renew focus, and fix the US operations, which were the 'primary reason for the company’s fall from grace'.
India orders unusual recall of reports on Apple antitrust probe: Report
”It is imperative that such information be maintained confidential, ensuring that no unauthorised disclosure occurs,” the watchdog, the CCI, said in a four-page order signed by its top four officials.
RateGain Q1 FY25 — a soft quarter, all eyes on acquisitions
The company has a track record of turning around acquired entities
Chart of the Day: India Inc is using its capital more efficiently than ever
The number of companies generating more than 15 percent return on equity has increased significantly from FY16-20
Safari Q1 FY25 – Is the weakness a trend reversal?
Diverse product offerings, channel mix, and a frugal approach to costs should stand the company in good stead
Fortis Healthcare’s diagnostic unit is a grown-up child who never leaves home
The diagnostics unit is facing growth headwinds amid change in brand name
VIP Industries: Can investors ride on the early green shoots?
Though competition is increasing, there are strong sectoral tailwinds and the opportunity size is big
Marico on Bangladesh unrest: 'We remain watchful…manufacturing operations to resume soon'
Bangladesh civil unrest has claimed nearly 500 lives so far. India and Bangladesh share over 4,000 km of land border.
Britannia Industries: Growth beyond core is the key
While top-line thrust is encouraging, non-core portfolio will drive growth and support margins.
JSW MG Motor India gears up to roll out Windsor e-CUV, anticipates 250% growth in EV sales in 2024
Positioned as an intelligent crossover utility vehicle, the company stated that the USP of this car will be the functionality of an SUV and the interior space of a sedan
What to be greedy about amid the heightened fear in markets?
Once the Fed starts cutting rates, there’s a high possibility that discretionary spending by enterprises will resume, brightening the outlook for IT service players
Sun Pharma: India remains bright spot amid uncertainty over hair loss drug
The company’s India business grew by more than 10 percent for four consecutive quarters outperforming the India pharma market
Business in the Week Ahead: August 5-9, 2024
RBI will release the monetary policy. Two new IPOs will open for subscription
Tata Motors Q1 results: Net profit zooms 74% on-year to Rs 5,566 crore, beats estimates
Tata Motors Q1 FY25 Results: JLR's revenue grew by 5.4 percent during April-June to GBP 7.3 billion with EBIT margins of 8.9 percent, up 30 basis points.
This long-term portfolio stock is now available at an attractive valuation
Mas Financial has reported a decent set of earnings with healthy asset quality
M&M's Q1 net profit falls 5% YoY to Rs 2,613 crore, SUV revenue market share rises
The Mumbai-based company's consolidated net profit went up by 20 percent at Rs 3,283 crore, as compared to Rs 2,745 crore in the year ago period
Chart of the Day: Why Suzlon's orders look more resilient this time
The company’s order book increased to the highest levels in its history in the June 2024 quarter
IndusInd Bank Q1 FY25: weak quarter, valuation attractive
The stock has headroom to re-rate if the bank handles asset quality stress well
Dr Reddy's Labs targets double-digit India growth for FY25
With sales of Rs 1,330 crore in Q1 of FY25, Dr. Reddy's ranks 10th in the domestic market, according to IQVIA data.
LVMH's luxury wares earn top billing at Olympics opening
Grammy-winner Lady Gaga delivered an energetic performance of Renee 'Zizi' Jeanmaire's "Mon truc en plumes" (My Feather Friend) decked out in a Dior Haute Couture black feather jacket over a black satin bustier.
Cipla forecasts US sales run-rate at $235-$240 mn, margin to be stable at current levels
Cipla is aiming for a Q4 FY25 launch for its important respiratory drug, Advair, while awaiting the US FDA's response on corrective measures at its Goa facility, crucial for launching the chemotherapy drug Abraxane.
Tech Mahindra Q1 FY25 – great start to a turnaround year
Revenue growth, expansion in margins, and a traction in deals hold out growth hopes
In its biggest acquisition, Mankind Pharma tries to replicate its past success in M&A
Mankind Pharma is acquiring BSV at an enterprise value of Rs 13,630 crore. The last major acquisition it did was for Rs 1,872 crore.
Mankind Pharma to buy Bharat Serums from Advent for Rs 13,630 crore
Earlier on July 25, Moneycontrol had reported that Mankind Pharma had edged ahead of EQT-ADIA consortium and emerged as the front-runner for the deal
